This study showed that trastuzumab-resistant ER+/HER2+ breast cancers carry genetic alterations that affect the DNA repair mechanism while trastuzumab-resistant ER−/HER2+ breast cancers carry mutations that activate mitotic signaling [82]. Here, ERBB2 is linked to breast cancer.